18 December 2020 - Deborah Wilkes
Merz Healthcare has released financial results, while Germany’s Diapharm is setting up a new branch in the UK for dealing with medical devices after Brexit.
Merz reports financial results
Germany’s Merz Healthcare reported sales of EUR982 million (USD1.20 billion) in the year ended 30 June 2020, representing a fall of 10.3% compared to the same period a year earlier.
Earnings Before Interest and Taxes (EBIT) dropped by 71.8% to EUR38.8 million, giving an EBIT margin of 4.0%.
The family-owned company – which comprises Merz Aesthetics, Merz Therapeutics and Merz Consumer Care – said the COVID-19 pandemic had contributed to the reduction in earnings.
In October 2020, Merz Consumer Care acquired a stake in the German startup Brooklyn Soap Company which markets natural care products for men.
Merz Consumer Care’s product portfolio includes Tetesept, which focuses on cough and cold remedies, personal care products, and vitamins, minerals and supplements (VMS), as well as Merz Spezial which focuses on skincare and VMS products.
Diapharm opens new UK branch
Germany’s Diapharm is setting up a new branch in the UK with effect from 1 January 2021 to “give manufacturers of medical devices continued access to the British market after Brexit”.
The pharmaceutical consulting firm said the move would give companies from the European Union a “way to satisfy the new rules for medical devices in the UK which will require all products to be registered with the Medicines and Healthcare products Regulatory Agency (MHRA) from 1 January 2021”.
Diapharm said this registration would be open only to companies based in the UK.
“The UK representative service is the logical next step in expanding our portfolio,” said Guido Middeler, who heads the medical devices team at Diapharm. “For years, our European Union representative service for market entry in the European Union has been a fixed point of contact for the international healthcare industry.”